MRC1 and urinary bladder carcinoma: Lynch-associated bladder cancers are usually MMR-deficient; thus, as with UTUC, any urothelial tumor in a known Lynch patient warrants MMR analysis, and eligible patients with advanced disease may receive immunotherapy [55,59].